• 1
    Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177:21062131.
  • 2
    American Cancer Society. Learn About Cancer: Initial treatment of prostate cancer by stage. Accessed May 8, 2013.
  • 3
    Davis BJ, Horwitz EM, Lee WR, et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy. 2012;11:619.
  • 4
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Prostate cancer. Updated 2013.
  • 5
    Makarov DV, Trock BJ, Humphreys EB, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 2007;69:10951101.
  • 6
    D'Amico AV, Whittington R, Malkowitz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969974.
  • 7
    Nag S, Beyer D, Friedland J, Grimm P, Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 1999;44:789799.
  • 8
    National Comprehensive Cancer Network. NCCN practice guidelines for prostate cancer. Posted 2000.
  • 9
    Arvold ND, Chen M-H, Moul JW, et al. Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease. J Urol. 2011;186:9196.
  • 10
    Shah C, Lanni Jr TB, Ghilezan MI, et al. Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer. Brachytherapy. 2012;11:441445.
  • 11
    Goldner G, Pötter R, Battermann JJ, et al. Comparison between external beam radiotherapy (70 Gy/74 Gy) and permanent interstitial brachytherapy in 890 intermediate risk prostate cancer patients. Radiother Oncol. 2012;103:223227.
  • 12
    Kibel AS, Ciezki JP, Klein EA, et al. Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol. 2012;187:12591265.
  • 13
    Lubeck DP, Litwin MS, Henning JM, et al. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. Urology. 1996;48:773777.
  • 14
    Prestidge B. RTOG 0232: a phase III study comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone for patients with intermediate risk prostatic carcinoma. Accessed June 13, 2013.
  • 15
    Frank SJ, Grimm PD, Sylvester JE, et al. Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: A survey of practice patterns in the United States. Brachytherapy. 2007;6:28.
  • 16
    Copeland LA, Elshaikh MA, Jackson J, Penner LA, Underwood W. Impact of brachytherapy on regional, racial, marital status, and age-related patterns of definitive treatment for clinically localized prostate carcinoma. Cancer. 2005;104:13721380.
  • 17
    Lee WR, Moughan J, Owen JB, Zelefsky MJ. The 1999 patterns of care study of radiotherapy in localized prostate carcinoma. Cancer. 2003;98:19871994.
  • 18
    Davis DA, Taylor-Vaisey A. Translating guidelines into practice: a systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines. Can Med Assoc J. 1997;157:408416.
  • 19
    Komaki R, Khalid N, Langer CJ, et al. Penetration of recommended procedures for lung cancer staging and management in the United States over 10 years: a quality research in radiation oncology survey. Int J Radiat Oncol Biol Phys. 2013;85:10821089.
  • 20
    Hattangadi JA, Taback N, Neville BA, Harris JR, Punglia RS. Accelerated partial breast irradiation using brachytherapy for breast cancer: patterns in utilization and guideline concordance. J Natl Cancer Inst. 2012;104:2941.
  • 21
    Zelefsky MJ, Kuban DA, Levy LB, et al. Multi-institutional analysis of long-term outcome for stages T1–T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2007;67:327333.
  • 22
    Potters L, Morgenstern C, Calugaru E, et al. 12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol. 2005;173:15621566.
  • 23
    Taira AV, Merrick GS, Butler WM, et al. Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 2011;79:13361342.
  • 24
    Cosset J-M, Flam T, Thiounn N, et al. Selecting patients for exclusive permanent implant prostate brachytherapy: the experience of the Paris Institut Curie/Cochin Hospital/Necker Hospital Group on 809 patients. Int J Radiat Oncol Biol Phys. 2008;71:10421048.
  • 25
    Uesugi T, Saika T, Edamura K, et al. Primary Gleason grade 4 impact on biochemical recurrence after permanent interstitial brachytherapy in Japanese patients with low- or intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82:e219e223.
  • 26
    O'Connor AM, Llewellyn-Thomas HA, Flood AB. Modifying unwarranted variations in health care: shared decision making using patient decision aids. Health Aff (Millwood). 2004;(suppl variation):VAR63VAR72.
  • 27
    Nattinger AB, Kneusel RT, Hoffmann RG, Gilligan MA. Relationship of distance from a radiotherapy facility and initial breast cancer treatment. J Natl Cancer Inst. 2001;93:13441346.
  • 28
    Shen X, Keith SW, Mishra MV, Dicker AP, Showalter TN. The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis. Int J Radiat Oncol Biol Phys. 2012;83:11541159.
  • 29
    Graham ID, Evans WK, Logan D, et al. Canadian oncologists and clinical practice guidelines: a national survey of attitudes and reported use. Oncology. 2000;59:283290.
  • 30
    Balas E, Boren S. Managing clincial knowledge for health care improvement. Yearbook of Medical Informatics. National Library of Medicine: Bethesda, MD; 2000:6570.
  • 31
    Eldefrawy A, Katkoori D, Abramowitz M, Soloway MS, Manoharan M. Active surveillance vs. treatment for low-risk prostate cancer: a cost comparison. Urol Oncol. 2013;31:576580.
  • 32
    Dinan MA, Robinson TJ, Zagar TM, et al. Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999-2007. Int J Radiat Oncol Biol Phys. 2012;82:e781e786.